- Home
- FORA vs THTX Comparison
FORA vs THTX Comparison
Compare FORA & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- THTX
- Stock Information
- Founded
- FORA 2014
- THTX 1993
- Country
- FORA United States
- THTX Canada
- Employees
- FORA N/A
- THTX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- THTX Health Care
- Exchange
- FORA Nasdaq
- THTX Nasdaq
- Market Cap
- FORA 63.8M
- THTX 54.3M
- IPO Year
- FORA N/A
- THTX N/A
- Fundamental
- Price
- FORA $2.01
- THTX $1.82
- Analyst Decision
- FORA Strong Buy
- THTX Hold
- Analyst Count
- FORA 1
- THTX 1
- Target Price
- FORA $5.00
- THTX N/A
- AVG Volume (30 Days)
- FORA 17.1K
- THTX 85.1K
- Earning Date
- FORA 11-13-2024
- THTX 10-10-2024
- Dividend Yield
- FORA N/A
- THTX N/A
- EPS Growth
- FORA N/A
- THTX N/A
- EPS
- FORA N/A
- THTX N/A
- Revenue
- FORA $19,709,723.00
- THTX $84,316,000.00
- Revenue This Year
- FORA N/A
- THTX $5.60
- Revenue Next Year
- FORA $13.59
- THTX $4.62
- P/E Ratio
- FORA N/A
- THTX N/A
- Revenue Growth
- FORA N/A
- THTX 5.75
- 52 Week Low
- FORA $1.97
- THTX $1.08
- 52 Week High
- FORA $4.15
- THTX $2.58
- Technical
- Relative Strength Index (RSI)
- FORA 48.22
- THTX 70.56
- Support Level
- FORA $1.99
- THTX $1.40
- Resistance Level
- FORA $2.05
- THTX $1.56
- Average True Range (ATR)
- FORA 0.05
- THTX 0.12
- MACD
- FORA -0.00
- THTX 0.03
- Stochastic Oscillator
- FORA 41.18
- THTX 96.65
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.